Edwards Lifesciences Corporation $EW Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 97.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,695 shares of the medical research company’s stock after selling 117,875 shares during the period. Edgestream Partners L.P.’s holdings in Edwards Lifesciences were worth $289,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of EW. BLI Banque de Luxembourg Investments acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $4,809,000. First National Advisers LLC boosted its position in shares of Edwards Lifesciences by 30.3% in the 2nd quarter. First National Advisers LLC now owns 41,484 shares of the medical research company’s stock valued at $3,245,000 after purchasing an additional 9,644 shares during the period. Berry Wealth Group LP acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $202,000. West Family Investments Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth about $208,000. Finally, Skandinaviska Enskilda Banken AB publ raised its holdings in Edwards Lifesciences by 15.2% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 1,090,051 shares of the medical research company’s stock worth $85,253,000 after buying an additional 143,603 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.6%

Edwards Lifesciences stock opened at $86.26 on Monday. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm has a market cap of $50.05 billion, a PE ratio of 37.18, a P/E/G ratio of 3.82 and a beta of 0.97. The firm’s 50 day moving average price is $80.95 and its two-hundred day moving average price is $78.76.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the business posted $0.67 EPS. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Stifel Nicolaus set a $100.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday. Citigroup upped their price target on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research note on Monday, November 3rd. Wells Fargo & Company reiterated an “overweight” rating and set a $96.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research report on Friday. Finally, UBS Group set a $92.00 target price on Edwards Lifesciences in a report on Friday. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $92.91.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.34% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.